Barclays Maintains Overweight on MetLife, Lowers Price Target to $89

Benzinga Newsdesk www.benzinga.com Negative 89.3%

Neg 89.3% Neu 0% Pos 0%

Barclays analyst Alex Scott maintains MetLife (NYSE:MET) with a Overweight and lowers the price target from $92 to $89.

Comments

No comments yet. Be the first!